Icosapent ethyl
Class
Hypolipidemic agents
Subclass
Omega-3 fatty acids
Substance name
Ethyl eicosapentaenoic acid (E-EPA)
Brand names
Vascepa®
Common formulations
Capsule
Dosage and administration
Adults patients
Treatment
Hypertriglyceridemia • Severe
Adjunctive treatment
Adjunctive treatment for hypertriglyceridemia • Mild-to-moderate, with established CVD or diabetes mellitus and ≥ 2 additional risk factors for CVD
Indications for use
Labeled indications
Adults
Safety risks
Contraindications
Hypersensitivity to icosapent ethyl or its components
Warnings and precautions
AF, atrial flutter
Allergic reactions
Bleeding
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource